Synairgen plc
('Synairgen' or the 'Company')
Results of Annual General Meeting and Appointment of New Chairman
Southampton, UK - 10 October 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces the results of voting at its Annual General Meeting today. All resolutions proposed at its Annual General Meeting were passed.
The full results of the proxy voting and text of the resolutions can be viewed by visiting the Company's website at www.synairgen.com/investors/aim-rule-26.
Following the announcement on 18 September, Dr. Mark Parry-Billings has now succeeded Simon Shaw as Chairman of the Board of Directors, effective immediately post today's AGM. Dr. Parry-Billings is an accomplished international biotech and pharmaceutical executive with a successful track record of more than 30 years heading R&D and leading businesses. Most recently, he served as Global Head of Drug Development at Chiesi. Prior to this, he served as CEO of Topigen Pharmaceuticals until its acquisition by Pharmaxis in 2010. Mark has deep expertise in respiratory therapeutics and drug delivery to the lungs, notably having led multiple novel respiratory assets from early stage through clinical development and to market approvals, with a primary focus on inhaled drug delivery.
For further enquiries, please contact:
Synairgen plc
Tel: + 44 (0) 23 8051 2800
Cavendish Capital Markets Limited (NOMAD and Joint Broker)
Geoff Nash, Camilla Hume, Trisyia Jamaludin (Corporate Finance)
Sunila de Silva (ECM)
Nigel Birks - Life Science Specialist Sales
Tel: + 44 (0) 20 7220 0500
Deutsche Numis (Joint Broker)
Freddie Barnfield, Duncan Monteith, Euan Brown
Tel: + 44 (0) 20 7260 1000
ICR Consilium (Financial Media and Investor Relations)
Mary-Jane Elliott, Namrata Taak, Lucy Featherstone
Tel: +44 (0) 20 3709 5700
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.
Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.
Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
